Preliminary Agenda
WELCOME AND OPENING REMARKS
Setting the Stage for the Day with an Overview of the Most Important Trends, Breakthroughs, and Opportunities Shaping the Future of Retinal Innovation
RETINA INNOVATION SHOWCASE
Application to present is now open!
THE RETINA STAR-UP LIFECYCLE: FROM DISCOVERY TO EXIT
Panel Moderator:
PANEL DISCUSSION:
Leaders across the Innovation Ecosystem Discuss How Retinal Technologies Move from Early Discovery through Clinical Development, Financing, Partnerships, and Successful Exits
John Pollack, MD, Partner, Illinois Retina Associates , Partner , Illinois Retina Associates
DURABLE THERAPIES IN RETINA: EXTENDING TREATMENT BEYOND MONTHLY INJECTIONS
Session Overview:
Innovators showcase next-generation therapies and drug delivery approaches designed to reduce treatment burden and move retina care beyond monthly anti-VEGF injections.
Applcation to present is now open!
THE END OF MONTHLY VEG-F: Hype or Reality?
Session Overview:
Experts examine the clinical, regulatory, and real-world challenges that will determine whether longer-acting retinal therapies can finally replace monthly treatment paradigms.
SPOTLIGHT ON DRY AMD/GA: Earlier Intervention in Retinal Disease
Session Overview:
Companies present emerging therapies and technologies aimed at enabling earlier detection and more effective treatment of dry AMD and geographic atrophy.
Application to present is now open!
THE GA DECISION POINT: Treat Earlier or Wait?
Session Overview:
Clinical and industry leaders discuss how advances in imaging, regulatory strategy, and treatment development may shift GA management from observation to intervention.
RESTORING VISION: INNOVATION IN INHERITED RETINAL DISEASE
Session Overview:
Leading companies highlight cutting-edge gene- and cell-therapy approaches targeting inherited retinal diseases with the potential for durable or transformative outcomes.
Application to present is now open!
REGULATORY INFLECTION POINTS IN RETINA: Shaping the Path from Development to Market
CAPITAL IN RETINA: WHAT GETS FUNDED, WHAT DOESN'T, AND WHY?
Session Overview:
Investors share insights into funding trends, investment priorities, and what differentiates retinal technologies that successfully attract venture capital.
WHERE RETINA IS HEADED: STRATEGIC R&D PERSPECTIVES
Session Overview:
Pharma and industry leaders discuss the scientific breakthroughs, therapeutic strategies, and technology platforms shaping the future of retinal innovation.